Brought to you in partnership with:In joint providership with:

October 30, 2017The Liberty Hotel

215 Charles StreetBoston, Massachusetts

Featuring expert faculty providing updates on the most promising targets for development of new cancer treatments.

Chabner Colloquium:Answering the Big Questions in Cancer Research2017 STO Annual Meeting

Monday, October 30, 2017

7:00AM Registration Opens

7:45AM Welcome and IntroductionMartin J. Murphy, DMedSc, PhD, Convener, Society for Translational OncologyBruce A. Chabner, MD, Massachusetts General Hospital Cancer Center, Harvard Medical School

Session 1: New Insights Into DNA Repair and Drug ResponseModerator: Antonio “Tito” Fojo, MD, PhD, Columbia University Cancer Center

8:00AM PARP Inhibitor Resistance and Acquired Vulnerability in Ovarian Cancer

Alan D’Andrea, MD, Dana-Farber Cancer Institute, Harvard Medical School

8:45AM Assessing DNA Repair in Clinical Trials Ted Hong, MD, Massachusetts General Hospital Cancer Center

9:30AM Targeting the ATR Kinase in Cancer Therapy Lee Zou, PhD, Massachusetts General Hospital Cancer Center

10:15-10:30AM Break/Exhibits

Session 2: Targets That Defy Effective TherapyModerator: Joseph R. Bertino, MD, Rutgers Cancer Institute of New Jersey

10:30AM Developing Therapies for Ras-driven Cancers Karen Cichowski, PhD, Brigham and Women’s Hospital, Harvard Medical School

11:15AM Is FGFR Inhibition an Effective Target in Gastrointestinal Tumors?

Lipika Goyal, MD, Massachusetts General Hospital Cancer Center

12:00PM Intergenic Fusions in Advanced HR+ Breast Cancer Leif Ellisen, MD, PhD, Massachusetts General Hospital Cancer Center

12:45PM Lunch Buffet and Exhibits 5th Floor Rotunda

Session 3: Promising Drug-antibody Conjugates and Cell Death Pathway InhibitorsModerator: Susan Bates, MD, Columbia University Cancer Center

1:30PM Genomic and Functional Characterization of Patient Derived Xenograft Models of Small Cell Lung Cancer

Anna Farago, MD, PhD, Massachusetts General Hospital Cancer Center

2:15PM Antibody Drug Conjugates for Triple Negative Breast Cancer: Targeting Positive in the Negative

Aditya Bardia, MD, MPH, Massachusetts General Hospital Cancer Center

3:00PM PARP in Breast Cancer Steven J. Isakoff, MD, PhD, Massachusetts General Hospital Cancer Center

3:45-4:00PM Break/Exhibits

Session 4: Junior Faculty Forum Moderator: Oliver Sartor, MD, Tulane University School of Medicine

4:00PM Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spherioids

Russell W. Jenkins, MD, PhD, Massachusetts General Hospital Cancer Center, Dana-Farber Cancer Institute

4:30PM Improving Therapy for EGFR-Mutant Lung Cancers Zofia Piotrowska, MD, Massachusetts General Hospital Cancer Center

5:00PM Financial Toxicity of Cancer Ryan Nipp, MD, MPH, Massachusetts General Hospital Cancer Center

5:30PM Closing Remarks and Adjourn

The content of each presentation does not necessarily reflect the views of the Society for Translational Oncology, The Oncologist, or The Massachusetts General Hospital or any of its affiliates.

Slides will not be printed for the meeting in an effort to protect the environment. Any requests for slides should be directed to the specific presenter as STO does not have permission to distribute slides on their behalf.

Meeting Agenda

2017 Chabner Colloquium: Answering the Big Questions in Cancer Research 2017 STO Annual Meeting

Jointly provided by: Brought to you in partnership with:

OverviewIn the field of oncology, the rapid pace of discovery and a better understanding of prevention, detection, the microenvironment, and treatment of cancer will lead to improved patient outcomes. Accurately tailored cancer treatment and individualized therapy will focus on tumor biology and host factors. The healthcare provider will need to be well informed in order to provide the most effective therapy for a particular patient with the fewest associated risks and toxicities. In oncology, our understanding of the complexity of the disease is expanding at an exponential rate.

Target AudienceThis activity is designed to meet the educational needs of physicians and scientists in academic and practice settings who wish to advance their knowledge of the research into new treatments and improve their competence in the care of patients with cancer.

AccreditationThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Society for Translational Oncology and The Massachusetts General Hospital. The Society for Translational Oncology is accredited by the ACCME to provide continuing medical education for physicians.

Credit DesignationThe Society for Translational Oncology designates this live activity for a maximum of 8.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME CreditIn order to receive CME credit, learners must sign in, review the CME information (accreditation, learning objectives, faculty disclosures, etc.) and attend the CME activity. Learners will be asked to complete an electronic activity evaluation following the meeting to indicate the number of credit hours claimed. Certificates will be provided upon completion of the evaluation.

To obtain CME credit, please visit: http://bit.ly/2017ChabnerCMECredit 

Acknowledgements STO gratefully acknowledges educational grants in partial support of this activity from:

THE PHYSICIAN PAYMENTS SUNSHINE ACT (SUNSHINE ACT) COMPLIANCE Effective August 1, 2013, The Centers for Medicare & Medicaid Services (CMS) required reporting of any direct or indirect payments made to any US Healthcare Professional by pharmaceutical and device manufacturers and applicable group purchasing organizations (GPOs) under its Open Payments program.

STO will comply with the requirements of those companies who have provided support for this CME activity regarding the appropriate reporting of all direct and indirect payments to healthcare professionals.

Amgen, Inc.EcoR1 CapitalLilly Oncology

Novartis Pharmaceuticals CorporationPfizer Inc

In accordance with ACCME Standards for Commercial Support and the policies of the Society for Translational Oncology (STO), persons participating in this activity who are in a position to control the content have disclosed all relevant relationships with any commercial interest. On the basis of disclosed information, STO identifies and resolves all conflicts of interest before delivery of content.

STO staff involved in the development of this activity have nothing to disclose.

The following faculty have indicated that they have had relevant financial relationship(s) with a commercial interest within the past 12 months or that they have nothing to disclose.

CME Faculty DisclosuresAditya Bardia, MD, MPHConsultant/advisory role: Pfizer, Novartis, Genentech, Spectrum PharmaResearch funding: Pfizer, Novartis, Genentech, Immunomedics, Mersana Therapeutics, Biotheranostics

Susan Bates, MDIntellectual property rights: CelgeneConsultant/advisory role: 4SC, AC Immune, Scandion Oncology

Joseph R. Bertino, MDNothing to disclose

Karen Cichowski, PhDConsultant/advisory role: Genentech

Alan D’Andrea, MDIntellectual property rights: Ideaya BiosciencesConsultant/advisory role: Third Rock Ventures, AstraZeneca, Ideaya Biosciences, Deerfield, Sierra Oncology, Intellia Therapeutics, EMD SeronoResearch funding: Eli Lilly

Leif Ellisen, MD, PhDNothing to disclose

Anna Farago, MD, PhDConsultant/advisory role: AbbVie, PharmaMarResearch funding: Bristol-Myers Squibb, AbbVie, PharmaMar, Loxo Oncology, Ignyta, AstraZeneca

Antonio “Tito” Fojo, MD, PhDConsultant/advisory role: Cerulean Pharmaceuticals

Lipika Goyal, MDConsultant/advisory role: DebioPharmHonoraria: Ribon Therapeutics

Ted Hong, MDConsultant/advisory role: Clinical GenomicsResearch funding: Taiho

Steven Isakoff, MD, PhDConsultant/advisory role: AbbVieResearch funding: AbbVie, Genentech, PharmaMar, Merck, OncoPep

Russell Jenkins, MD, PhDNothing to disclose

Ryan Nipp, MD, MPHNothing to disclose

Zofia Piotrowska, MDConsultant/advisory role: AstraZeneca, Ariad Pharmaceuticals, Guardant Health

A. Oliver Sartor, MDConsultant/advisory role: AstraZeneca, Bayer, Bellicum Pharmaceuticals, Bristol-Myers Squibb, Celgene, Dendreon, EMD Serono, Johnson & Johson, OncoGenex, Pfizer, Sanofi, TokaiResearch funding: Bayer, Endocyte, Innocrin, Johnson & Johnson, Sanofi

Lee Zou, PhDConsultant/advisory role: Loxo Oncology

Financial Disclosures

Learning Objectives

At the conclusion of this meeting, participants will be better able to:

• Discuss the integration of tumor profiling, non-invasive biomarker development, and use of animal models into trial design for molecular-based drug development.

• Describe the technical hurdles for the translation of molecular-based drug development into agents for routine oncologic practice.

• Evaluate the potential of molecular-based drug development for improving reults of treatment of common and rare tumors.